Abstract:Understanding of the molecular mechanism and biological implication underlying the difference in binding of substrate peptides and small-molecule inhibitors to multidrug-resistant mutants of HIV-1 protease would help to develop new anti-HIV agents combating drug resistance. Here, an integration of rigorous quantum mechanics/molecular mechanics (QM/MM) analysis and empirical Poisson–Boltzmann/surface area (PB/SA) model is described to investigate the structural basis and energetic property of wild-type HIV-1 protease and its mutants in recognizing and binding with a wide variety of ligands, including the peptides derived from its cognate cleavage sites and the cleavage site variants as well as a number of FDA-approved protease inhibitors, attempting to explain why is substrate binding unsusceptible to most observed HIV-1 protease mutations. A preliminary test study demonstrates that the combined QM/MM–PB/SA scheme is able to effectively reproduce the relative ligand binding energy changes upon protease single- and double-mutations, albeit the absolute values appear to be different significantly between the calculated and experimental results. With the QM/MM–PB/SA calculations a complete mutation energy map of HIV-1 protease–ligand interactions is created, which unravels distinct affinity pictures of wild-type substrates, substrate variants and, particularly, the protease inhibitors bound to HIV-1 protease mutants, suggesting that, on the one hand, the evaluation pressure under anti-HIV chemotherapies addresses site-directed protease mutations that impair and undermine the intermolecular interactions specific to inhibitors but not substrates; on the other hand, co-evaluation of protease and its substrate peptides provides a more effective mechanism to avoid therapeutic surveillance. Further, nonbonded interaction analysis and computational alanine scanning reveal 12 key residues that is critical for substrate binding, from which the Asn25, Gly27, Ala28, Asp29 and Pro81 are identified that have not yet been found to cause drug resistance and hence would be the promising sites targeted by new protease inhibitors.

A Case of Septic Arthritis of the Shoulder Due to Yersinia enterocolitica with Review of the Literature

A Comparative Insight into Amprenavir Resistance of Mutations V32i, G48v, I50v, I54v, and I84v in Hiv-1 Protease Based on Thermodynamic Integration and Mm-Pbsa Methods

Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance

Quantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions

Exploring Drug-Resistant Mechanisms of I84V Mutation in HIV-1 Protease Toward Different Inhibitors by Thermodynamics Integration and Solvated Interaction Energy Method

Some Insights into Mechanism for Binding and Drug Resistance of Wild Type and I50V V82A and I84V Mutations in HIV-1 Protease with GRL-98065 Inhibitor from Molecular Dynamic Simulations.

Why is Substrate Peptide Binding Unsusceptible to Multidrug-Resistant Mutations in HIV-1 Protease? A Structural and Energetic Analysis

Evaluating The Potency Of Hiv-1 Protease Drugs To Combat Resistance

Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657

Contrasting the effect of hinge region insertions and non-active site mutations on HIV protease-inhibitor interactions: Insights from altered flap dynamics

Systematic Investigation on Interactions for HIV Drug Resistance and Cross-Resistance among Protease Inhibitors

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Advanced Molecular Mechanisms of Modified DRV Compounds in Targeting HIV-1 Protease Mutations and Interrupting Monomer Dimerization

Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region

Study The Interaction Between The HIV-1 Protease and Its Mutations With Inhibitor GRL-0519 by The Computational Method

Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.

Detecting and Understanding Combinatorial Mutation Patterns Responsible for HIV Drug Resistance

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients

Prediction of HIV-1 Protease Inhibitor Resistance using a Protein–Inhibitor Flexible Docking Approach

Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease